These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 34282198)

  • 1. Meta-regression of randomized control trials with antithrombotics: weak correlation between net clinical benefit and all cause-mortality.
    Kilo R; Laporte S; Arab R; Mainbourg S; Provencher S; Grenet G; Bertoletti L; Villeneuve L; Cucherat M; Lega JC;
    Sci Rep; 2021 Jul; 11(1):14728. PubMed ID: 34282198
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessment of clinically relevant bleeding as a surrogate outcome for major bleeding: validation by meta-analysis of randomized controlled trials.
    Laporte S; Chapelle C; Bertoletti L; Ollier E; Zufferey P; Lega JC; Merah A; Décousus H; Schulman S; Meyer G; Cucherat M; Mismetti P
    J Thromb Haemost; 2017 Aug; 15(8):1547-1558. PubMed ID: 28544422
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Efficacy and safety of non-vitamin K antagonist versus vitamin K antagonist oral anticoagulants in the prevention and treatment of thrombotic disease in active cancer patients: a systematic review and meta-analysis of randomized controlled trials].
    Wang CX; Wu D; Yang PP; Wu QH
    Zhonghua Xin Xue Guan Bing Za Zhi; 2020 Aug; 48(8):689-696. PubMed ID: 32847326
    [No Abstract]   [Full Text] [Related]  

  • 4. Oral anticoagulants for primary prevention, treatment and secondary prevention of venous thromboembolic disease, and for prevention of stroke in atrial fibrillation: systematic review, network meta-analysis and cost-effectiveness analysis.
    Sterne JA; Bodalia PN; Bryden PA; Davies PA; López-López JA; Okoli GN; Thom HH; Caldwell DM; Dias S; Eaton D; Higgins JP; Hollingworth W; Salisbury C; Savović J; Sofat R; Stephens-Boal A; Welton NJ; Hingorani AD
    Health Technol Assess; 2017 Mar; 21(9):1-386. PubMed ID: 28279251
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Non-valvular atrial fibrillation patients with none or one additional risk factor of the CHA2DS2-VASc score. A comprehensive net clinical benefit analysis for warfarin, aspirin, or no therapy.
    Lip GY; Skjøth F; Nielsen PB; Larsen TB
    Thromb Haemost; 2015 Oct; 114(4):826-34. PubMed ID: 26223245
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Secondary prevention of recurrent venous thromboembolism after initial oral anticoagulation therapy in patients with unprovoked venous thromboembolism.
    Robertson L; Yeoh SE; Ramli A
    Cochrane Database Syst Rev; 2017 Dec; 12(12):CD011088. PubMed ID: 29244199
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Non-vitamin K antagonist oral anticoagulants and major bleeding-related fatality in patients with atrial fibrillation and venous thromboembolism: a systematic review and meta-analysis.
    Caldeira D; Rodrigues FB; Barra M; Santos AT; de Abreu D; Gonçalves N; Pinto FJ; Ferreira JJ; Costa J
    Heart; 2015 Aug; 101(15):1204-11. PubMed ID: 26037103
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Net Clinical Benefit of Non-vitamin K Antagonist Oral Anticoagulants for Venous Thromboembolism Prophylaxis in Patients With Cancer: A Systematic Review and Trade-Off Analysis From 9 Randomized Controlled Trials.
    Yan YD; Zhang C; Shen L; Su YJ; Liu XY; Wang LW; Gu ZC
    Front Pharmacol; 2018; 9():575. PubMed ID: 29946255
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improved outcomes with European Society of Cardiology guideline-adherent antithrombotic treatment in high-risk patients with atrial fibrillation: a report from the EORP-AF General Pilot Registry.
    Lip GY; Laroche C; Popescu MI; Rasmussen LH; Vitali-Serdoz L; Dan GA; Kalarus Z; Crijns HJ; Oliveira MM; Tavazzi L; Maggioni AP; Boriani G
    Europace; 2015 Dec; 17(12):1777-86. PubMed ID: 26321406
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Net Clinical Benefit of Oral Anticoagulation Among Older Adults With Atrial Fibrillation.
    Shah SJ; Singer DE; Fang MC; Reynolds K; Go AS; Eckman MH
    Circ Cardiovasc Qual Outcomes; 2019 Nov; 12(11):e006212. PubMed ID: 31707823
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Net clinical benefit of dabigatran vs. warfarin in venous thromboembolism: analyses from RE-COVER
    Feuring M; Schulman S; Eriksson H; Kakkar AJ; Schellong S; Hantel S; Schueler E; Kreuzer J; Goldhaber SZ
    J Thromb Thrombolysis; 2017 May; 43(4):484-489. PubMed ID: 28210989
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Thromboembolic Risk, Bleeding Outcomes and Effect of Different Antithrombotic Strategies in Very Elderly Patients With Atrial Fibrillation: A Sub-Analysis From the PREFER in AF (
    Patti G; Lucerna M; Pecen L; Siller-Matula JM; Cavallari I; Kirchhof P; De Caterina R
    J Am Heart Assoc; 2017 Jul; 6(7):. PubMed ID: 28736385
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Percutaneous left atrial appendage closure for stroke prevention in patients with atrial fibrillation: an assessment of net clinical benefit.
    Gangireddy SR; Halperin JL; Fuster V; Reddy VY
    Eur Heart J; 2012 Nov; 33(21):2700-8. PubMed ID: 23008509
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effectiveness and Safety of Non-vitamin K Antagonist Oral Anticoagulants for Atrial Fibrillation and Venous Thromboembolism: A Systematic Review and Meta-analyses.
    Almutairi AR; Zhou L; Gellad WF; Lee JK; Slack MK; Martin JR; Lo-Ciganic WH
    Clin Ther; 2017 Jul; 39(7):1456-1478.e36. PubMed ID: 28668628
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and Safety of Apixaban Versus Warfarin in Patients With Atrial Fibrillation and Extremes in Body Weight.
    Hohnloser SH; Fudim M; Alexander JH; Wojdyla DM; Ezekowitz JA; Hanna M; Atar D; Hijazi Z; Bahit MC; Al-Khatib SM; Lopez-Sendon JL; Wallentin L; Granger CB; Lopes RD
    Circulation; 2019 May; 139(20):2292-2300. PubMed ID: 30773022
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of extended-duration thromboprophylaxis on venous thromboembolism and major bleeding among acutely ill hospitalized medical patients: a bivariate analysis.
    Chi G; Goldhaber SZ; Kittelson JM; Turpie AGG; Hernandez AF; Hull RD; Gold A; Curnutte JT; Cohen AT; Harrington RA; Gibson CM
    J Thromb Haemost; 2017 Oct; 15(10):1913-1922. PubMed ID: 28762617
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of extended thromboprophylaxis for medically ill patients. A meta-analysis of randomised controlled trials.
    Dentali F; Mumoli N; Prisco D; Fontanella A; Di Minno MN
    Thromb Haemost; 2017 Feb; 117(3):606-617. PubMed ID: 28078350
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparing mortality in patients with atrial fibrillation who are receiving a direct-acting oral anticoagulant or warfarin: a meta-analysis of randomized trials.
    Liew A; O'Donnell M; Douketis J
    J Thromb Haemost; 2014 Sep; 12(9):1419-24. PubMed ID: 24986568
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Net Clinical Benefit of Left Atrial Appendage Closure Versus Warfarin in Patients With Atrial Fibrillation: A Pooled Analysis of the Randomized PROTECT-AF and PREVAIL Studies.
    Brouwer TF; Whang W; Kuroki K; Halperin JL; Reddy VY
    J Am Heart Assoc; 2019 Dec; 8(23):e013525. PubMed ID: 31752643
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of differences in medical costs when new oral anticoagulants are used for the treatment of patients with non-valvular atrial fibrillation and venous thromboembolism vs warfarin or placebo in the US.
    Amin A; Bruno A; Trocio J; Lin J; Lingohr-Smith M
    J Med Econ; 2015 Jun; 18(6):399-409. PubMed ID: 25586203
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.